Why the study?
Does alpha human atrial natriuretic polypeptide alter systemic hemodynamics and coronary circulation in patients with ischemic heart disease?
Does alpha human atrial natriuretic polypeptide alter systemic hemodynamics and coronary circulation in patients with ischemic heart disease?
Intravenous infusion of alpha-hANP in patients with ischemic heart disease significantly reduces systemic and coronary vascular resistance while increasing myocardial oxygen consumption.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating in a single case; leaves open whether alpha-hANP improves outcomes in ischemic heart disease.
Serizawa et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: